NCT07421544

Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines

A Prospective, Phase 4, Multicenter, Open-label Pilot Study of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Goldman, Butterwick, Fitzpatrick and Groff · Academic / Other
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Accepted

Summary

Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60 days.

Detailed description

100 patients total who demonstrate mild-to-moderate signs of facial aging, including volume loss, fine lines, and skin laxity will receive up to two treatments with Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid gel. Patients will return for follow up visits at day 14 and day 60 where they will undergo standardized 2D photography, VISIA photography and assessments.

Conditions

• Fine Lines
• Wrinkle
• Facial Laxity
• Volume Loss

Interventions

Type	Name	Description
OTHER	Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid	Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid is a sterile, biodegradable, homogenized and isotonic HA gel that uses an innovative crosslinking technology (MACRO Core Technology) to achieve a stable 3D HA matrix

Timeline

• Start date: 2026-03-01
• Primary completion: 2026-05-15
• Completion: 2026-07-01
• First posted: 2026-02-19
• Last updated: 2026-02-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study